Inflammatory microglial and astroglial phenotype associated with pathological alpha-synuclein inclusions in the substantia nigra
Objective: To characterize neuroinflammatory gene expression in microglia and astrocytes associated with early alpha-synuclein (a-syn) inclusion formation. Background: Parkinson’s disease (PD) is characterized by alpha-synuclein…The effect of short-term treadmill exercise in the alpha-synuclein preformed fibril rat model of Parkinson’s disease
Objective: To determine how treadmill exercise impacts behavior and Parkinson-related pathology in the alpha-synuclein (a-syn) preformed fibril (PFF) model. Background: Exercise is often recommended by…Mosaicism for somatic SNCA copy number variants in multiple system atrophy is related to pathological subtype and presence of α-synuclein inclusions
Objective: To investigate the correlation of somatic copy number variants (CNVs) of the alpha-synuclein gene (SNCA) in multiple system atrophy (MSA) with disease subtype, and…Blood-derived α-synuclein from Parkinson´s disease patients is able to seed pathology
Objective: To identify seeding capacities of soluble α-synuclein (α-syn) conformers derived from neuronal extracellular vesicles (NEs) from Parkinson´s disease (PD) patients. Background: PD pathology is…Protein aggregation and calcium dysregulation are the earliest hallmarks of synucleinopathy in enriched iPSC-derived human midbrain dopaminergic neurons
Objective: Develop and adapt a differentiation paradigm to produce enriched hiPSC-derived midbrain dopaminergic neurons (mDA), to resolve the temporal sequence of pathophysiological events in synucleinopathies.…CSF biomarkers in neurodegenerative parkinsonism can distinguish between multiple system atrophy and 4-repeat tauopathies, but not between disease with Lewy bodies and multiple system atrophy
Objective: To assess the usefulness of a defined set of blood-based and cerebrospinal fluid-based biomarkers in the differential diagnosis of neurodegenerative proteinopathies. Background: The diagnostic…GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease
Objective: Demonstrate the involvement of our structurally targeted allosteric regulator Parkinson’s disease (PD) candidate, GT-02287, in decreasing the CBE-induced neurotoxic effect and in restoring lysosomal…Design of a prodromal screening study for subtypes in Parkinson’s Disease
Objective: To follow-up prodromal Parkinson’s Disease (PD) subtypes in a longitudinal cohort study, validating new biomarkers and ethical guidelines for early detection of PD. Background:…Multidimensional phenotyping of human stem cell-derived midbrain dopaminergic neurons from a SNCA triplication carrier for drug screening applications
Objective: We hypothesized that combining multiple Parkinson's disease (PD) relevant cellular phenotypes will increase the accuracy, stability, and usability of human midbrain dopaminergic (mDA) neuronal…Genetic stratification of motor and quality of life outcomes in Parkinson’s disease in the EARLYSTIM study
Objective: We identified (Weiss et al., 2016) that single nucleotide polymorphism (SNPs) of the alpha-synuclein gene (SNCA) predicted the motor effect of subthalamic nucleus stimulation (STN-DBS)…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 51
- Next Page »